Herpes Zoster in Hematological Disorders: Pathogenesis, Risk Stratification, and Emerging Strategies for Prevention and Immunization
European Journal of Haematology · 2026-01 · 116 (1) · 14-22
DOI: 10.1111/ejh.70049 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 07.10.2025. Verfasst von Enrica Antonia Martino und 10 weiteren Autor:innen. Beteiligte Einrichtung: Haematology Unit, Department of Onco-Haematology, AO of Cosenza, Cosenza, Italy. Hauptthemen laut MEDLINE: Herpes Zoster, Herpesvirus 3, Human, Hematologic Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PNRR-MAD-2022-12375673.
Abstract (Originalsprache)
Background
Herpes zoster (HZ), resulting from reactivation of latent varicella‐zoster virus (VZV), imposes a significant burden on immunocompromised patients, particularly those with hematological malignancies and recipients of hematopoietic stem cell transplants (HSCT). These populations face markedly increased risks of severe complications, including disseminated disease and postherpetic neuralgia.
Objective
This review examines the pathogenesis, epidemiology, risk factors, and evolving preventive strategies for HZ in patients with hematological disorders, with an emphasis on antiviral prophylaxis and vaccination.
Methods
Relevant data from recent clinical trials, observational studies, and international guidelines were critically reviewed to evaluate the burden of HZ and the effectiveness of prophylactic interventions in immunocompromised populations.
Results
Immunosuppression—whether due to the underlying disease or post‐transplant immune reconstitution—compromises VZV‐specific cellular immunity, thereby increasing HZ susceptibility. Incidence rates in high‐risk groups, such as HSCT recipients or patients treated with proteasome inhibitors, JAK2 inhibitors, or CAR‐T therapies, may exceed 30–60 per 1000 person‐years. Antiviral prophylaxis remains a fundamental preventive approach. The adjuvanted recombinant zoster vaccine (aRZV) demonstrates 68%–87% efficacy even in heavily immunosuppressed individuals. Emerging vaccine platforms, including mRNA‐based formulations, offer promising improvements in immunogenicity and scalability.
Conclusion
Patients with hematological conditions are particularly vulnerable to HZ. Effective prevention requires a tailored combination of antiviral prophylaxis and aRZV immunization. The development of mRNA‐based vaccines may further enhance preventive strategies for this at‐risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Haematology Unit, Department of Onco-Haematology, AO of Cosenza, Cosenza, Italy.
- Department of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy.
- AIL Sezione di Cosenza, Cosenza, Italy.
- Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.
ORCID-Profile: Antonella Bruzzese, Massimo Gentile
Förderung
- PNRR-MAD-2022-12375673
Zitieren
APA
Martino, E. A., Vigna, E., Bruzzese, A., Amodio, N., Lucia, E., Olivito, V., Labanca, C., Caserta, S., Mendicino, F., Morabito, F., & Gentile, M. (2026). Herpes Zoster in Hematological Disorders: Pathogenesis, Risk Stratification, and Emerging Strategies for Prevention and Immunization. European Journal of Haematology, 116(1), 14-22. https://doi.org/10.1111/ejh.70049
Vancouver
Martino EA, Vigna E, Bruzzese A, Amodio N, Lucia E, Olivito V, et al. Herpes Zoster in Hematological Disorders: Pathogenesis, Risk Stratification, and Emerging Strategies for Prevention and Immunization. European Journal of Haematology. 2026;116(1):14-22. doi:10.1111/ejh.70049
BibTeX
@article{Martino2026,
author = {Martino, Enrica Antonia and Vigna, Ernesto and Bruzzese, Antonella and Amodio, Nicola and Lucia, Eugenio and Olivito, Virginia and Labanca, Caterina and Caserta, Santino and Mendicino, Francesco and Morabito, Fortunato and Gentile, Massimo},
title = {Herpes Zoster in Hematological Disorders: Pathogenesis, Risk Stratification, and Emerging Strategies for Prevention and Immunization},
journal = {European Journal of Haematology},
year = {2026},
volume = {116},
number = {1},
pages = {14--22},
doi = {10.1111/ejh.70049}
}
EUVIMED